Bluebird Bio To Present Additional Long-Term Follow-up Data From Gene Therapy Programs In Sickle Cell Disease And Beta-Thalassemia At The 66th ASH Annual Meeting and Exposition
Bluebird Bio To Present Additional Long-Term Follow-up Data From Gene Therapy Programs In Sickle Cell Disease And Beta-Thalassemia At The 66th ASH Annual Meeting and Exposition
bluebird bio將在第66屆ASH年會暨博覽會上發佈鐮狀細胞病和β地中海貧血基因治療項目的額外長期隨訪數據
bluebird bio, Inc. (NASDAQ:BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia who require regular blood transfusions will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will take place December 7-10, 2024 at the San Diego Convention Center and online.
美國公司bluebird bio，Inc.（納斯達克：BLUE）今日宣佈，將在第66屆美國血液學會（ASH）年會和博覽會上發佈其鑲嵌病毒載體（LVV）基因增加計劃在患有疼痛性血細胞病史和需要定期輸血的β地中海貧血患者中的新數據和更新數據。 會議將於2024年12月7日至10日在聖迭戈會議中心和在線上舉行。
資訊熱榜
更新時間